Co-expression of insulin-like growth factor-1 and interleukin-4 in an in vitro inflammatory model

Cytokine

Volumn 50, Issue 3, 2010, Pages 297-305

  Manning, Kizzie ^a   Rachakonda, P Sivaramakrishna ^a   Rai, Muhammad Farooq ^a   Schmidt, Michael F G ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Arthritis; IGF 1; IL 4; Inflammation; Pro inflammatory cytokines

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4; PROTEOGLYCAN; SOMATOMEDIN C;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE REGENERATION; TRANSGENE; UPREGULATION;

AGGRECANS; ANIMALS; CHONDROCYTES; COLLAGEN TYPE II; DOGS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-4; MATRIX METALLOPROTEINASES; MODELS, IMMUNOLOGICAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TRANSFECTION;

EID: 77952541151     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.01.010     Document Type: Article

References (45)

1. McQuillan D.J., Handley C.J., Campbell M.A., Bolis S., Milway V.E., Herington A.C. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986, 240:423-430.
2. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
3. Rechler M.M. Insulin-like growth factor binding proteins. Vitam Horm 1993, 47:1-114.
4. Chevalier X., Tyler J.A. Production of binding proteins and role of the insulin-like growth factor I binding protein 3 in human articular cartilage explants. Br J Rheumatol 1996, 35:515-522.
5. Neidel J. Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:81-84.
6. Olney R.C., Tsuchiya K., Wilson D.M., Mohtai M., Maloney W.J., Schurman D.J., et al. Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. J Clin Endocrinol Metab 1996, 81:1096-1103.
7. Porter R.M., Akers R.M., Howard R.D., Forsten-Williams K. Transcriptional and proteolytic regulation of the insulin-like growth factor-I system of equine articular chondrocytes by recombinant equine interleukin-1beta. J Cell Physiol 2006, 209:542-550.
8. Dore S., Pelletier J.P., DiBattista J.A., Tardif G., Brazeau P., Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding proteins. Arthritis Rheum 1994, 37:253-263.
9. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., Heinegard D., van Den Berg W.B. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999, 163:5049-5055.
10. Olney R.C., Wilson D.M., Mohtai M., Fielder P.J., Smith R.L. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995, 146:279-286.
11. van Roon J.A., van Roy J.L., Gmelig-Meyling F.H., Lafeber F.P., Bijlsma J.W. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996, 39:829-835.
12. Nishisaka F., Sohen S., Fukuoka H., Okamoto Y., Matukawa M., Fukuda K., et al. Interleukin-4 reversed the interleukin-1-inhibited proteoglycan synthesis through the inhibition of NO release: a possible involvement of intracellular calcium ion. Pathophysiology 2001, 7:289-293.
13. Amin A.R., Di Cesare P.E., Vyas P., Attur M., Tzeng E., Billiar T.R., et al. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 1995, 182:2097-2102.
14. Martel-Pelletier J., Alaaeddine N., Pelletier J.P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999, 4:D694-D703.
15. Studer R.K., Levicoff E., Georgescu H., Miller L., Jaffurs D., Evans C.H. Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRbeta tyrosine phosphorylation. Am J Physiol Cell Physiol 2000, 279:C961-C969.
16. Taskiran D., Stefanovic-Racic M., Georgescu H., Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994, 200:142-148.
17. Fernandes J.C., Martel-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246.
18. Hart P.H., Vitti G.F., Burgess D.R., Whitty G.A., Piccoli D.S., Hamilton J.A. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989, 86:3803-3807.
19. Rachakonda P.S., Rai M.F., Schmidt M.F. Application of inflammation-responsive promoter for an in vitro arthritis model. Arthritis Rheum 2008, 58:2088-2097.
20. Wondimu A., Veit M., Kohn B., Kaul S., Hoffmann A., Brunnberg L., et al. Molecular cloning, expression and characterization of the Canis familiaris interleukin-4. Cytokine 2001, 16:88-92.
21. Madry H., Padera R., Seidel J., Langer R., Freed L.E., Trippel S.B., et al. Gene transfer of a human insulin-like growth factor I cDNA enhances tissue engineering of cartilage. Hum Gene Ther 2002, 13:1621-1630.
22. Rai M.F., Rachakonda P.S., Manning K., Palissa C., Sittinger M., Ringe J., et al. Molecular and phenotypic modulations of primary and immortalized canine chondrocytes in different culture systems. Res Vet Sci 2009, 87:399-407.
23. Madry H., Trippel S.B. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Ther 2000, 7:286-291.
24. Rai M.F., Rachakonda P.S., Manning K., Vorwerk B., Brunnberg L., Kohn B., et al. Quantification of cytokines and inflammatory mediators in a three-dimensional model of inflammatory arthritis. Cytokine 2008, 42:8-17.
25. Asahina I., Sampath T.K., Hauschka P.V. Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res 1996, 222:38-47.
26. Martel-Pelletier J., Di Battista J.A., Lajeunesse D., Pelletier J.P. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998, 47:90-100.
27. Rachakonda P.S., Rai M.F., Manning K., Schmidt M.F. Expression of canine interleukin-4 in canine chondrocytes inhibits inflammatory cascade through STAT 6. Cytokine 2008, 44:179-184.
28. Wurster A.L., Withers D.J., Uchida T., White M.F., Grusby M.J. Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis. Mol Cell Biol 2002, 22:117-126.
29. Gingras S., Cote S., Simard J. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Mol Endocrinol 2000, 14:229-240.
30. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 20:203-212.
31. Backer J.M., Schroeder G.G., Kahn C.R., Myers M.G., Wilden P.A., Cahill D.A., et al. Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J Biol Chem 1992, 267:1367-1374.
32. Backer J.M., Myers M.G., Shoelson S.E., Chin D.J., Sun X.J., Miralpeix M., et al. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992, 11:3469-3479.
33. Baltensperger K., Kozma L.M., Jaspers S.R., Czech M.P. Regulation by insulin of phosphatidylinositol 3′-kinase bound to alpha- and beta-isoforms of p85 regulatory subunit. J Biol Chem 1994, 269:28937-28946.
34. Tardif G., Reboul P., Pelletier J.P., Geng C., Cloutier J.M., Martel-Pelletier J. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis Rheum 1996, 39:968-978.
35. Hui W., Rowan A.D., Cawston T. Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1alpha. Ann Rheum Dis 2001, 60:254-261.
36. Zhang M., Zhou Q., Liang Q.Q., Li C.G., Holz J.D., Tang D., et al. IGF-1 regulation of type II collagen and MMP-13 expression in rat endplate chondrocytes via distinct signaling pathways. Osteoarthritis Cartilage 2008, 17:100-106.
37. Im H.J., Pacione C., Chubinskaya S., Van Wijnen A.J., Sun Y., Loeser R.F. Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem 2003, 278:25386-25394.
38. van Lent P.L., Holthuysen A.E., Sloetjes A., Lubberts E., van Den Berg W.B. Local overexpression of adeno-viral IL-4 protects cartilage from metallo proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthritis Cartilage 2002, 10:234-243.
39. van Roon J.A., Lafeber F.P., Bijlsma J.W. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001, 44:3-12.
40. Verschure P.J., Joosten L.A., van De Loo F.A., van Den Berg W.B. IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints. Ann Rheum Dis 1995, 54:976-982.
41. Schalkwijk J., Joosten L.A., van Den Berg W.B., van de Putte L.B. Chondrocyte nonresponsiveness to insulin-like growth factor 1 in experimental arthritis. Arthritis Rheum 1989, 32:894-900.
42. Haupt J.L., Frisbie D.D., McIlwraith C.W., Robbins P.D., Ghivizzani S., Evans C.H., et al. Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res 2005, 23:118-126.
43. Tyler J.A. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989, 260:543-548.
44. Mi Z., Ghivizzani S.C., Lechman E.R., Jaffurs D., Glorioso J.C., Evans C.H., et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000, 43:2563-2570.
45. Madry H., Zurakowski D., Trippel S.B. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Ther 2001, 8:1443-1449.